Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Strong Q2 Innovative Medicines division performance
Innovative Medicines
Sandoz
Group
Q2 2021
Net sales
Core Oplnc
Core
Core margin
change vs. PY
% CC1
change vs. PY
% CC1
margin
%1
change vs. PY
%pts cc1
10
Q2 2021 ex. PY forward purchasing de-stocking²
Net sales
change vs. PY
%, cc1
Core Oplnc
Core margin
change vs. PY
%, CC1
change vs. PY
%pts cc1
14
37.3
1.3
7
6
-0.2
3
21.7
-0.4
-1
-1.8
3
33.5
1.2
5
4
-0.3
9
13
1. Core results, constant currencies and free cash flow are non-IFRS measures. Further details regarding non-IFRS measures can be found starting on page 48 of the Condensed Financial Report. 2. Growth ex. PY forward purchasing
de-stocking is a non-IFRS measure; explanation can be found on page 61 of Condensed Interim Financial Report.
34 Investor Relations | Q2 2021 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation